Roivant Sciences Ltd. (ROIV) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Roivant Sciences Ltd. Do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences Ltd. (ROIV) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Matthew Gline and employs approximately 860 people. With a market capitalization of $19.9B, ROIV is one of the prominent companies in the Healthcare sector.
Roivant Sciences Ltd. (ROIV) Stock Rating — Hold (April 2026)
As of April 2026, Roivant Sciences Ltd. receives a Hold rating with a composite score of 44.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ROIV ranks #817 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Roivant Sciences Ltd. ranks #56 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ROIV Stock Price and 52-Week Range
Roivant Sciences Ltd. (ROIV) currently trades at $28.24. The stock lost $0.24 (0.8%) in the most recent trading session. The 52-week high for ROIV is $30.33, which means the stock is currently trading -6.9% from its annual peak. The 52-week low is $8.73, putting the stock 223.5% above its annual trough. Recent trading volume was 3.1M shares, reflecting moderate market activity.
Is ROIV Overvalued or Undervalued? — Valuation Analysis
Roivant Sciences Ltd. (ROIV) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.99x, versus the sector average of 2.75x. The price-to-sales ratio is 1345.76x, compared to 1.66x for the average Healthcare stock.
At current multiples, Roivant Sciences Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Roivant Sciences Ltd. Profitability — ROE, Margins, and Quality Score
Roivant Sciences Ltd. (ROIV) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -12.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -12.2% versus the sector average of -33.1%.
On a margin basis, Roivant Sciences Ltd. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -13157.9% (sector: -66.1%). Net profit margin stands at -9393.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -55.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ROIV Debt, Balance Sheet, and Financial Health
Roivant Sciences Ltd. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 30.66x, indicating strong short-term liquidity.
ROIV has a beta of 0.88, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Roivant Sciences Ltd. is 65/100, reflecting average volatility within the normal range for its sector.
Roivant Sciences Ltd. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Roivant Sciences Ltd. reported revenue of $15M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-636M. Operating income came in at $-1.20B.
In Q3 2026, Roivant Sciences Ltd. reported revenue of $2M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-314M. Revenue grew -77.8% year-over-year compared to Q3 2025. Operating income came in at $-339M.
In Q2 2026, Roivant Sciences Ltd. reported revenue of $2M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-166M. Revenue grew -64.9% year-over-year compared to Q2 2025. Operating income came in at $-306M.
In Q1 2026, Roivant Sciences Ltd. reported revenue of $2M and earnings per share (EPS) of $-0.33. Net income for the quarter was $-274M. Revenue grew -96.1% year-over-year compared to Q1 2025. Operating income came in at $-285M.
Over the past 8 quarters, Roivant Sciences Ltd. has experienced revenue contraction from $55M to $15M. Investors analyzing ROIV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ROIV Dividend Yield and Income Analysis
Roivant Sciences Ltd. (ROIV) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ROIV Momentum and Technical Analysis Profile
Roivant Sciences Ltd. (ROIV) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ROIV vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Roivant Sciences Ltd. (ROIV) ranks #56 out of 838 stocks based on the Blank Capital composite score. This places ROIV in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ROIV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ROIV vs S&P 500 (SPY) comparison to assess how Roivant Sciences Ltd. stacks up against the broader market across all factor dimensions.
ROIV Next Earnings Date
No upcoming earnings date has been announced for Roivant Sciences Ltd. (ROIV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ROIV? — Investment Thesis Summary
Roivant Sciences Ltd. presents a balanced picture with arguments on both sides. The quality score of 30/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers. Low volatility (stability score 65/100) reduces downside risk.
In summary, Roivant Sciences Ltd. (ROIV) earns a Hold rating with a composite score of 44.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ROIV stock.
Related Resources for ROIV Investors
Explore more research and tools: ROIV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ROIV head-to-head with peers: ROIV vs AZN, ROIV vs SLGL, ROIV vs VMD.